VRAX
ヴィラックス・バイオラボ
Virax Biolabs Group Limited
閉場中RVOL 0.9xDV $66,92020日平均DV $74,786?
52W high -83.0%52W low +2140.0%Market cap $407,589Avg volume 34K
Company Overview
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q4 | -12.64 | $12,423 | -$5M |
| 2025 Q2 | -12.25 | $1,608 | -$3M |
| 2025 Q4 | -19.00 | $1,378 | -$3M |
| 2024 Q2 | -22.25 | $4,953 | -$2M |
| 2024 Q4 | -42.75 | $79,919 | -$3M |
| 2023 Q2 | -41.00 | $76,500 | -$4M |
|
